Crossject
Crossject
ALCJ
EURONEXT
2.20
EUR
10.55%
About
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research.
The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The Company has industrial partnerships with Hirtenberger and Recipharm. It provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 104.6K |
| Three Month Average Volume | 1.6M |
| High Low | |
| Fifty-Two Week High | 5.908 EUR |
| Fifty-Two Week Low | 1.52 EUR |
| Fifty-Two Week High Date | 11 Jan 2024 |
| Fifty-Two Week Low Date | 17 Jun 2024 |
| Price and Volume | |
| Current Price | 2.195 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 14.39% |
| Thirteen Week Relative Price Change | 10.91% |
| Twenty-Six Week Relative Price Change | -32.13% |
| Fifty-Two Week Relative Price Change | -50.10% |
| Year-to-Date Relative Price Change | -56.05% |
| Price Change | |
| One Day Price Change | -5.79% |
| Thirteen Week Price Change | 6.04% |
| Twenty-Six Week Price Change | -34.78% |
| Five Day Price Change | -1.13% |
| Fifty-Two Week Price Change | -47.71% |
| Year-to-Date Price Change | -55.45% |
| Month-to-Date Price Change | -5.79% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.04847 EUR |
| Book Value Per Share (Most Recent Quarter) | 0.04847 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.24192 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.24192 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.19708 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00391 EUR |
| Revenue Per Share (Trailing Twelve Months) | 0.00391 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | -99999.99 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.23291 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.23291 EUR |
| Normalized (Last Fiscal Year) | -0.24678 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.23291 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.23291 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -0.23291 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -0.23291 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.06235 EUR |
| Cash Per Share (Most Recent Quarter) | 0.06235 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -0.11147 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -0.11182 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.33985 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2,340 |
| Cash Flow Revenue (Trailing Twelve Months) | -8,692 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -7,934.48% |
| Pretax Margin (Last Fiscal Year) | -7,934.48% |
| Pretax Margin (5 Year) | -2,290.39% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 1,885.52% |
| Gross Margin (Trailing Twelve Months) | 1,885.52% |
| Gross Margin (5 Year) | 952.59% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -7,592.41% |
| Operating Margin (Trailing Twelve Months) | -7,592.41% |
| Operating Margin (5 Year) | -2,234.20% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -5,957.24% |
| Net Profit Margin (Trailing Twelve Months) | -5,957.24% |
| Net Profit Margin (5 Year) | -1,896.57% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -37.20% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -71.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -84.80% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 14.36% |
| Total Debt (5 Year) | 23.74% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 19.85% |
| EPS Change (Trailing Twelve Months) | 23.44% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 16.5M |
| Net Debt (Last Fiscal Year) | 16.5M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 625 |
| Price to Sales (Trailing Twelve Months) | 625 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 45 |
| Price to Book (Most Recent Quarter) | 45 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 855 |
| Long Term Debt to Equity (Most Recent Quarter) | 855 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | 1 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -12,604,000 |
| Free Cash Flow (Trailing Twelve Months) | -12,604,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -17 |
| Net Interest Coverage (Trailing Twelve Months) | -17 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 1.0K |
| Total Debt to Equity (Most Recent Quarter) | 1.0K |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -28.09% |
| Return on Assets (Trailing Twelve Months) | -28.09% |
| Return on Assets (5 Year) | -32.43% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -144.53% |
| Return on Equity (Trailing Twelve Months) | -144.53% |
| Return on Equity (5 Year) | -158.47% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -42.26% |
| Return on Investment (Trailing Twelve Months) | -42.26% |
| Return on Investment (5 Year) | -44.26% |